| Sep 13 |
Moment Of Truth Approaches For Pyxis Oncology
|
| Aug 29 |
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
|
| Aug 15 |
Pyxis Oncology GAAP EPS of -$0.29
|
| Aug 14 |
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
|
| Aug 8 |
Pyxis Oncology draws Buy at Stifel on lead asset
|
| Jul 29 |
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
|
| Jun 28 |
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Jun 20 |
Institutional owners may ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) recent US$25m market cap decline as longer-term profits stay in the green
|
| Jun 10 |
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
|
| Jun 10 |
Pyxis Oncology: Promising Research Amid Cash Constraints
|
